Rallybio Corp
For the period ended Sep 30, 2026. Filed Oct 27, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 27, 2026
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity
Condensed Consolidated Statements of Changes in Stockholders' Equity
| FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 · COMMON · ADDITIONAL PAID-INCAPITAL · ACCUMULATED DEFICIT · ACCUMULATED OTHER COMPREHENSIVE GAIN · STOCKHOLDERS' EQUITY | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · SHARES · AMOUNT | ||||||||||||
| June 30, 2025 | 5,213,366 | $4 | $358,105 | $(312,162) | $17 | $45,964 | ||||||
| Share-based compensation | — | — | 1,047 | — | — | 1,047 | ||||||
| Issuance of common stock under the stock award plan | 28,586 | — | — | — | — | — | ||||||
| Net income | — | — | — | 16,016 | — | 16,016 | ||||||
| Other comprehensive gain | — | — | — | — | 7 | 7 | ||||||
| Balance, September 30, 2025 | 5,241,952 | $4 | $359,152 | $(296,146) | $24 | $63,034 | ||||||
| June 30, 2026 | 5,306,894 | $4 | $361,103 | $(266,611) | $— | $94,496 | ||||||
| Share-based compensation | — | — | 405 | — | — | 405 | ||||||
| Issuance of common stock under the stock award plan | 2,085 | — | — | — | — | — | ||||||
| Issuance of common stock from exercise of stock options | 24,211 | — | 120 | — | — | 120 | ||||||
| Net loss | — | — | — | (2,725) | — | (2,725) | ||||||
| Balance, September 30, 2026 | 5,333,190 | $4 | $361,628 | $(269,336) | $— | $92,296 | ||||||
| FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 · COMMON · ADDITIONAL PAID-INCAPITAL · ACCUMULATED DEFICIT · ACCUMULATED OTHER COMPREHENSIVE GAIN (LOSS) · STOCKHOLDERS' EQUITY | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · SHARES · AMOUNT | |||||||||||||
| December 31, 2024 | 5,188,743 | $4 | $354,602 | $(293,020) | $68 | $61,654 | |||||||
| Share-based compensation | — | — | 4,540 | — | — | 4,540 | |||||||
| Issuance of common stock under the stock award plan | 48,834 | — | — | — | — | — | |||||||
| Issuance of common stock under the stock purchase plan | 4,375 | — | 10 | — | — | 10 | |||||||
| Net loss | — | — | — | (3,126) | — | (3,126) | |||||||
| Other comprehensive loss | — | — | — | — | (44) | (44) | |||||||
| Balance, September 30, 2025 | 5,241,952 | $4 | $359,152 | $(296,146) | $24 | $63,034 | |||||||
| December 31, 2025 | 5,283,321 | $4 | $359,932 | $(301,998) | $18 | $57,956 | |||||||
| Share-based compensation | — | — | 1,442 | — | — | 1,442 | |||||||
| Issuance of common stock under the stock award plan | 8,769 | — | — | — | — | — | |||||||
| Issuance of common stock under the stock purchase plan | 2,802 | — | 13 | — | — | 13 | |||||||
| Issuance of common stock from exercise of stock options | 38,298 | — | 241 | — | — | 241 | |||||||
| Net income | — | — | — | 32,662 | — | 32,662 | |||||||
| Other comprehensive loss | — | — | — | — | (18) | (18) | |||||||
| Balance, September 30, 2026 | 5,333,190 | $4 | $361,628 | $(269,336) | $— | $92,296 | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.